Neurosense Therapeutics Ltd (NRSN) — Financial Flexibility Index
Neurosense Therapeutics Ltd (NRSN) has a Financial Flexibility Index of -0.71x as of December 2025. Free cash flow of $-1.83 Million (operating CF $-1.84 Million minus capex $1.50K) represents -1% of total liabilities ($2.59 Million). Check asset allocation strategy of Neurosense Therapeutics Ltd to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Neurosense Therapeutics Ltd Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for Neurosense Therapeutics Ltd across 7 annual periods. See Neurosense Therapeutics Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Neurosense Therapeutics Ltd (2019–2025)
Year-by-year free cash flow to debt coverage for Neurosense Therapeutics Ltd. For the full company profile including market capitalisation, see Neurosense Therapeutics Ltd market cap and net worth.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.96x | $-7.66 Million | $-7.67 Million | $2.59 Million | ▲ +41.8% |
| 2024 | -5.09x | $-10.13 Million | $-10.13 Million | $1.99 Million | ▼ -202.1% |
| 2023 | -1.68x | $-8.32 Million | $-8.35 Million | $4.94 Million | ▲ +53.2% |
| 2022 | -3.59x | $-7.52 Million | $-7.59 Million | $2.09 Million | ▼ -472.7% |
| 2021 | -0.63x | $-1.52 Million | $-1.54 Million | $2.42 Million | ▲ +89.0% |
| 2020 | -5.72x | $-686.00K | $-695.00K | $120.00K | ▲ +63.2% |
| 2019 | -15.54x | $-575.00K | $-582.00K | $37.00K | — |